文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症微环境中的趋化因子及其在癌症免疫治疗中的相关性。

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.

作者信息

Nagarsheth Nisha, Wicha Max S, Zou Weiping

机构信息

Department of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, Michigan 48109, USA.

Graduate Programs in Immunology and Tumour Biology, University of Michigan, Ann Arbor, Michigan 48109, USA.

出版信息

Nat Rev Immunol. 2017 Sep;17(9):559-572. doi: 10.1038/nri.2017.49. Epub 2017 May 30.


DOI:10.1038/nri.2017.49
PMID:28555670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5731833/
Abstract

The tumour microenvironment is the primary location in which tumour cells and the host immune system interact. Different immune cell subsets are recruited into the tumour microenvironment via interactions between chemokines and chemokine receptors, and these populations have distinct effects on tumour progression and therapeutic outcomes. In this Review, we focus on the main chemokines that are found in the human tumour microenvironment; we elaborate on their patterns of expression, their regulation and their roles in immune cell recruitment and in cancer and stromal cell biology, and we consider how they affect cancer immunity and tumorigenesis. We also discuss the potential of targeting chemokine networks, in combination with other immunotherapies, for the treatment of cancer.

摘要

肿瘤微环境是肿瘤细胞与宿主免疫系统相互作用的主要场所。不同的免疫细胞亚群通过趋化因子与趋化因子受体之间的相互作用被募集到肿瘤微环境中,这些细胞群体对肿瘤进展和治疗结果具有不同的影响。在本综述中,我们聚焦于人类肿瘤微环境中发现的主要趋化因子;详细阐述它们的表达模式、调控机制及其在免疫细胞募集以及癌症和基质细胞生物学中的作用,并探讨它们如何影响癌症免疫和肿瘤发生。我们还讨论了联合其他免疫疗法靶向趋化因子网络用于癌症治疗的潜力。

相似文献

[1]
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.

Nat Rev Immunol. 2017-9

[2]
CCL7 Signaling in the Tumor Microenvironment.

Adv Exp Med Biol. 2020

[3]
The chemokine network: a target in cancer biology?

Adv Drug Deliv Rev. 2006-10-1

[4]
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.

Int J Mol Sci. 2021-9-10

[5]
Chemokine systems in oncology: From microenvironment modulation to nanocarrier innovations.

Int J Biol Macromol. 2024-5

[6]
Improving homing in T cell therapy.

Cytokine Growth Factor Rev. 2017-6-23

[7]
Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.

J Pathol. 2010-12-10

[8]
Role of chemokine receptors in thyroid cancer and immunotherapy.

Endocr Relat Cancer. 2019-8

[9]
Chemokines in cancer.

Cancer Immunol Res. 2014-12

[10]
Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.

Mol Immunol. 2019-12-10

引用本文的文献

[1]
Synthesis, preclinical evaluation and clinical application of a novel heterodimeric tracer Ga-pentixafor-c(RGDfK) for PET-CT imaging.

Eur J Nucl Med Mol Imaging. 2025-9-9

[2]
SMC2 as a potential prognostic biomarker in lung adenocarcinoma and its correlation with immune microenvironment.

Mol Clin Oncol. 2025-8-12

[3]
Identification of potential drug targets and possible drugs for esophageal carcinoma from genetic insights: a comprehensive two-sample Mendelian randomization study.

Discov Oncol. 2025-8-25

[4]
Chemokines: humble yet mighty players in the tumour microenvironment.

Front Immunol. 2025-8-7

[5]
Targeting STING to disrupt macrophage-mediated adhesion in encapsulating peritoneal sclerosis.

Commun Biol. 2025-8-23

[6]
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

J Immunother Cancer. 2025-8-11

[7]
Predicting head and neck cancer response to radiotherapy with a chemokine-based model.

Sci Rep. 2025-8-4

[8]
Biased antagonism of a series of bicyclic CXCR2 intracellular allosteric modulators.

Front Pharmacol. 2025-7-14

[9]
Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 T cell infiltration.

Oncoimmunology. 2025-12

[10]
Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.

Biomolecules. 2025-7-11

本文引用的文献

[1]
Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.

Oncoimmunology. 2016-8-12

[2]
Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.

Oncoimmunology. 2015-9-2

[3]
Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.

Cancer Res. 2016-6-1

[4]
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Cell. 2016-5-19

[5]
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Sci Transl Med. 2016-3-2

[6]
Biological and pathological activities of interleukin-22.

J Mol Med (Berl). 2016-5

[7]
Ectopic expression of the chemokine CXCL17 in colon cancer cells.

Br J Cancer. 2016-3-15

[8]
CCR9 in cancer: oncogenic role and therapeutic targeting.

J Hematol Oncol. 2016-2-16

[9]
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

Cancer Res. 2016-1-15

[10]
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Science. 2015-11-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索